PASTEUR Act

Hozzl · 2025-01-04T11:17:50Z

Explore the details of House Bill 2940 PASTEUR Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

1/4/2025, 11:17 AM

Summary of Bill HR 2940

The PASTEUR Act, also known as Bill 118 hr 2940, is a piece of legislation currently being considered by the US Congress. The purpose of this bill is to establish a program within the Department of Health and Human Services that would support research and development efforts to combat emerging infectious diseases.

Specifically, the PASTEUR Act aims to enhance the nation's preparedness for potential pandemics by investing in research on new vaccines, treatments, and diagnostics. The bill would provide funding for the development of medical countermeasures to address emerging infectious diseases, such as novel viruses or drug-resistant bacteria.

Additionally, the PASTEUR Act seeks to improve coordination between federal agencies, academic institutions, and private sector partners in order to streamline the research and development process. By fostering collaboration and information sharing, the bill aims to accelerate the development of new medical countermeasures and ensure that the United States is better equipped to respond to future public health threats. Overall, the PASTEUR Act represents a bipartisan effort to strengthen the nation's ability to respond to emerging infectious diseases and protect the health and safety of the American people. If passed, this legislation has the potential to significantly enhance our preparedness for future pandemics and save lives.

Congressional Summary of HR 2940

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act of 2023

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 2940

Bill HR 2940 is currently in the status of Bill Introduced since April 27, 2023. Bill HR 2940 was introduced during Congress 118 and was introduced to the House on April 27, 2023. Bill HR 2940's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024

Bipartisan Support of Bill HR 2940

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

182

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 2940

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures

- Advanced technology and technological innovations

- Advisory bodies

- Appropriations

- Department of Health and Human Services

- Drug therapy

- Executive agency funding and structure

- Government information and archives

- Government studies and investigations

- Health information and medical records

- Infectious and parasitic diseases

- Medical research

- Prescription drugs

- Public contracts and procurement

- Research and development

Alternate Title(s) of Bill HR 2940

PASTEUR Act

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023

To amend title III of the Public Health Service Act to establish a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections, and for other purposes.